Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
<1125> NUCLEIC ACID-BASED TECHNIQUES -- GENERAL | APPENDICES | USP43–NF38 | 7865 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Appendix 2: Delete the Row for dNTP dinucleotide triphosphate |
RALTEGRAVIR TABLETS | DEFINITION | USP43–NF38 | 3834 | 24-Apr-2020 | 1-May-2020 | NA | NA | Change (C20H20FN6O5) to: (C20H21FN6O5) |
RALTEGRAVIR CHEWABLE TABLETS | PERFORMANCE TESTS/Dissolution <711> | USP43–NF38 | 3835 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Analysis: Change Mr1 = molecular weight of raltegravir, 444.44 to: Mr1 = molecular weight of raltegravir, 444.42 |
ALOSETRON HYDROCHLORIDE | IMPURITIES/Organic Impurities | USP43–NF38 | 141 | 24-Apr-2020 | 1-May-2020 | NA | NA | In System suitability/Suitability requirements/Resolution: Change NLT 7 to: NLT 3 |
CALCIUM AND VITAMIN D WITH MINERALS TABLETS | STRENGTH | USP43–NF38 | 4845 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Calcium, Copper, Magnesium, Manganese, and Zinc, Method 2/Acceptance criteria: Change NLT 90.0%–125.0% to: 90.0%–125.0% |
DAPSONE TABLETS | IDENTIFICATION/B. | USP43–NF38 | 1241 | 24-Apr-2020 | 1-May-2020 | NA | NA | Change Ultraviolet Absorption <197U> to: Spectroscopic Identification Tests <197>, Ultraviolet-Visible Spectroscopy: 197U |
WATER-SOLUBLE VITAMINS TABLETS | STRENGTH | USP43–NF38 | 5512 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Biotin, Method 3/Solid-phase extraction: Change anion-xchange to: anion-exchange AND In the Calculate statement in Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis: Delete ,… Read More |
EPINEPHRINE | IMPURITIES/Enantiomeric Purity | USP43–NF38 | Online | 24-Apr-2020 | 1-May-2020 | NA | NA | This erratum applies to the USP-NF ONLINE platform only. In System suitability solution: Change 0.03 mg/mL of in Mobile phase to: 0.03 mg/mL of USP Racepinephrine Hydrochloride RS in Mobile phase |
POLYOXYL 35 CASTOR OIL | IDENTIFICATION/C. Identity by Fatty Acid Composition | USP43–NF38 | 5956 | 24-Apr-2020 | 1-May-2020 | NA | NA | In System suitability/Suitability requirements/Relative standard deviation: Change linoeate to: linoleate |
MENADIONE | ASSAY/Procedure | USP43–NF38 | 2780 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Endpoint detection: Change Potentiometric to: Visual |
<191> IDENTIFICATION TESTS—GENERAL | CHEMICAL IDENTIFICATION TESTS | USP43–NF38 | 6587 | 24-Apr-2020 | 1-Aug-2020 | NA | NA | In Bicarbonate/B.: Change (1:20) to: (1 in 20) AND In Borate/A.: Change (1:50): to: (1 in 50): AND In Calcium/A.: Change (1:20) to: (1 in 20) AND In Carbonate/B.:… Read More |
PROPOFOL | IMPURITIES/Organic Impurities, Procedure 2 | USP43–NF38 | 3739 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Table 3: Delete Propofol related compound Bb 0.8 1.0 0.05 AND Change Propofol related compound Ac to: Propofol related compound Ab AND Change b2,6-Diisopropylbenzoquinone. … Read More |
RALTEGRAVIR TABLETS | IMPURITIES/Organic Impurities | USP43–NF38 | 3834 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Analysis: Change Mr1 = molecular weight of raltegravir, 444.44 to: Mr1 = molecular weight of raltegravir, 444.42 |
VITAMIN A TABLETS | ASSAY/Procedure 2 | USP43–NF38 | 4635 | 24-Apr-2020 | 1-May-2020 | NA | NA | In the variable definition list in Analysis: Change Sample solution 1 to: Sample solution |
ITRACONAZOLE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 1 | Revision Bulletin (Official August 01, 2019) | Online | 27-Mar-2020 | 1-Apr-2020 | NA | NA | In System suitability/Suitability requirements/Relative standard deviation: Change NMT 2.0% for 5 replicate injections to: NMT 2.0% for 5 replicates |
ANTITHROMBIN III HUMAN | SPECIFIC TESTS | USP42–NF37 | 350 | 27-Mar-2020 | 1-Apr-2020 | NA | NA | In Pyrogen Test <151>: Change USP Antithrombin III Units to: Antithrombin III IU |
ANTITHROMBIN III HUMAN | ADDITIONAL REQUIREMENTS | USP42–NF37 | 350 | 27-Mar-2020 | 1-Apr-2020 | NA | NA | In Labeling: Change USP Antithrombin III Units. to: Antithrombin III IU. |
CALCIUM ACETATE CAPSULES | PERFORMANCE TESTS/Dissolution <711> | Revision Bulletin (Official January 01, 2020) | Online | 28-Feb-2020 | 1-Mar-2020 | NA | NA | In Test 1/Analysis: Change dissolved at time point (i): Resulti = (rU/rS) × CS × V × D × (1/L) × 100 to: dissolved: … Read More |
FLUNIXIN MEGLUMINE INJECTION | IMPURITIES/Organic Impurities | USP42–NF37 | 1890 | 28-Feb-2020 | 1-Mar-2020 | NA | NA | In Sensitivity solution: Change in Diluent from the Standard solution to: in Diluent |
LITHIUM CARBONATE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 1 | USP42–NF37 | 2598 | 28-Feb-2020 | 1-Mar-2020 | NA | NA | In Analysis: Change V = volume of Medium, 900 mL to: V = volume of Medium, 800 mL |
DICLOXACILLIN SODIUM CAPSULES | PERFORMANCE TESTS | USP42–NF37 | 1330 | 28-Feb-2020 | 1-Mar-2020 | NA | NA | In Dissolution <711>: Change Sample solution: Sample per the chapter. Dilute with Medium to a concentration that is similar to the Standard solution. Tolerances: NLT 75% (Q) of the labeled amount of… Read More |
ALFADEX | CHEMICAL INFORMATION | USP42–NF37 | 5561 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | Change 972.84 to: 972.85 |
MEROPENEM FOR INJECTION | ASSAY/Procedure | Second Supplement to USP42–NF37 | 9216 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | In Mobile phase: Change Solution A to: Buffer |
POLYETHYLENE GLYCOL | CHEMICAL INFORMATION | USP42–NF37 | 5882 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | See https://www.uspnf.com/sites/default/files/usp_pdf/EN/january-2020-errata-with-image.pdf for correction |
CYPROHEPTADINE HYDROCHLORIDE ORAL SOLUTION | IMPURITIES/Organic Impurities | USP42–NF37 | 1195 | 27-Dec-2019 | 1-Jan-2020 | NA | NA | In Standard solution: Change in Solution B to: in Diluent |
<121> INSULIN ASSAYS | ASSAY/Rabbit Blood Sugar Method—Quantitative | Revision Bulletin (Official May 01, 2019) | Online | 27-Dec-2019 | 1-Jan-2020 | NA | NA | In Standard stock solution: Change of USP Insulin RS of the appropriate species to: of the USP Insulin Reference Standard of the appropriate species AND In Sample stock solution: Change of USP Insulin RS of the appropriate species.… Read More |
CUPRIC CHLORIDE | REAGENTS AND REFERENCE TABLES/Reagent Specifications | USP42–NF37 | 6092 | 27-Dec-2019 | 1-Jan-2020 | NA | NA | Change [7447-39-4]. to: [10125-13-0]. |
<857> ULTRAVIOLET-VISIBLE SPECTROSCOPY | QUALIFICATION OF UV-VIS SPECTROMETERS | Second Supplement to USP42–NF37 | 9570 | 27-Dec-2019 | 1-Jan-2020 | NA | NA | In all instances in Table 4: Change < to: ≤ AND In Control of Photometric Response/Acidic Nicotinic Acid Solutions in 0.1 N Hydrochloric Acid/paragraph 1: Change Using nicotinic acid solutions, the absorbance accuracy… Read More |
SIMVASTATIN TABLETS | PERFORMANCE TESTS/Dissolution <711> | USP42–NF37 | 4009 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Standard solution: Change USP Simvastatin RS in Medium to: USP Simvastatin RS in Medium. Transfer a portion of the solution to a centrifuge tube containing about 10 mg of Prewashed manganese dioxide per milliliter of… Read More |
<1227> VALIDATION OF MICROBIAL RECOVERY FROM PHARMACOPEIAL ARTICLES | VALIDATION OF NEUTRALIZATION METHODS—RECOVERY COMPARISONS | Second Supplement to USP42–NF37 | 9616 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In paragraph 1 in Recovery on Agar Medium: Change If it is necessary to solubilize the test stample, to: If it is necessary to solubilize the test sample, |
MEFENAMIC ACID CAPSULES | PERFORMANCE TESTS/Dissolution <711> | USP42–NF37 | 2711 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change Solution A, Mobile phase, Standard solution, Sample solution, Chromatographic system, and System suitability: Proceed as directed in the Assay, making any necessary volumetric adjustments. to: … Read More |
0.1 N POTASSIUM HYDROXIDE VS | REAGENTS AND REFERENCE TABLES/Solutions | USP42–NF37 | 6185 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change Standardization: Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N potassium hydroxide VS. Titrate with 0.1 N hydrochloric acid VS until a permanent pale-pink color is produced. to: Standardization: Add 2 drops of phenolphthalein TS… Read More |
ROPINIROLE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711> | Revision Bulletin (Official July 01, 2019) | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Test 2 and Test 3 in Analysis: Change Result1 = C1 × (1/L) × (Mr1/Mr2) × 100 to: Result1 = C1 × V × (1/L… Read More |
ZIPRASIDONE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 3/Tier 2 | Revision Bulletin (Official October 01, 2019) | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Buffer: Change 6.8 g/L g to: 6.8 g/L AND In Standard stock solution 2: Change Standard stock solution to: Standard stock solution 1 |
<1430> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—GENERAL | 1. OVERVIEW: GENERAL CHAPTERS BASED ON SCATTERING PHENOMENA | Second Supplement to USP42–NF37 | 9634 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Row 6 of Column 4 in Table 1: Change Also properties of condensated phrases to: Also properties of condensated phases |
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS | IMPURITIES/Organic Impurities | Second Supplement to USP42–NF37 | 9101 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Table 4, Footnote h: Change 0.47, to: 0.45, |
25% TETRABUTYLAMMONIUM HYDROXIDE TS | REAGENTS AND REFERENCE TABLES/Solutions | Second Supplement to USP42–NF37 | 9336 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change Transfer about 34.82 g to: Transfer about 77.1 g |
SODIUM BICARBONATE | IMPURITIES/Carbonate/Analysis | USP42–NF37 | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Remove the external reference to a reagent in Sodium Bicarbonate |
2,5-DIHYDROXYBENZOIC ACID | REAGENTS AND REFERENCE TABLES/Reagent Specifications | USP42–NF37 | 6097 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change [303-07-1]. to: [490-79-9]. |
<1430.5> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—SMALL ANGLE X-RAY SCATTERING AND SMALL ANGLE NEUTRON SCATTERING | 6. EXPERIMENTAL CONSIDERATIONS | Second Supplement to USP42–NF37 | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In 6.2 Resolution/6.2.1 Size resolution: Change qmin < π/dmax π/dmax to: qmin < π/dmax |
<1228.4> DEPYROGENATION BY RINSING | ROUTINE PROCESS CONTROL | USP42–NF37 | 8067 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In the first paragraph: Change WFI to: Water for Injection |
<55> BIOLOGICAL INDICATORS—RESISTANCE PERFORMANCE TESTS | D-VALUE DETERMINATION | USP42–NF37 | 6385 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In the third paragraph in Procedure: Change stated spore filter to: stated spore titer |
GADOTERIDOL | Limit of gadoteridol related compound A | USP42–NF37 | 2020 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In Chromatographic system: Change packing L21 to: packing L47 |
<1229.2> STEAM STERILIZATION OF AQUEOUS LIQUIDS | BIOBURDEN/BIOLOGICAL INDICATOR METHOD/Routine Process Control | USP42–NF37 | 8082 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In the first paragraph: Change calibrartion to: calibration |
<1222> TERMINALLY STERILIZED PHARMACEUTICAL PRODUCTS—PARAMETRIC RELEASE | INTRODUCTION | USP42–NF37 | 8021 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In paragraphs 4 and 5: Change a probability of a PNSU to: a PNSU |
HYPROMELLOSE ACETATE SUCCINATE | ASSAY | USP42–NF37 | 5772 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In Content of Methoxy and 2-Hydroxypropoxy Groups/Analysis: Change Result = (rUM/rSM) × (CS/CU) × (Mr1/Mr2) to: Result… Read More |
<2022> MICROBIOLOGICAL PROCEDURES FOR ABSENCE OF SPECIFIED MICROORGANISMS—NUTRITIONAL AND DIETARY SUPPLEMENTS | BUFFER AND MEDIA/Media | USP42–NF37 | 8514 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In Row 5 of Column 2 for L-Cystine in Fluid Selenite–Cystine Medium: Change 10.0 g to: 10.0 mg |
AMIODARONE HYDROCHLORIDE | CHEMICAL INFORMATION | USP42–NF37 | 253 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | See https://www.uspnf.com/sites/default/files/usp_pdf/EN/september-2019-errata-with-image.pdf for correction. |
DESFLURANE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 1230 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In USP Desflurane Related Compound A RS: Change Bis-(1,2,2,2-tetrafluoroethyl)ether. to: Bis-(1,2,2,2-tetrafluoroethyl)ether; Also known as: 1,1,1,2-Tetrafluoro-2-(1,2,2,2-tetrafluoroethoxy)ethane. |
BENZALDEHYDE | ASSAY/Procedure | USP42–NF37 | 5586 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In Chromatographic system: Delete Detector temperature: 25° |